BPC-157, a synthetic stable gastric pentadecapeptide derived from a protein found in human gastric juice, has been extensively investigated in preclinical animal models and in vitro systems for its cytoprotective, regenerative, and pleiotropic effects, primarily through mechanisms involving modulation of the nitric oxide (NO) system, upregulation of vascular endothelial growth factor (VEGF) expression and VEGFR2 signaling via pathways such as Akt-eNOS and ERK1/2, promotion of angiogenesis, fibroblast proliferation, collagen synthesis, and cell migration, while reducing pro-inflammatory cytokine levels and oxidative stress. Studies in rodent models of musculoskeletal injuries demonstrate accelerated healing of tendons, ligaments, muscles, bones, and fractures, with improved biomechanical strength, structural integrity, and functional recovery; similar protective and reparative outcomes appear in gastrointestinal tract lesions (e.g., ulcers, fistulas, anastomoses), skin wounds (including alkali-burn and excisional models), corneal transparency maintenance, and various organ systems (e.g., counteracting ischemia/reperfusion damage in heart, liver, and nerves), positioning BPC-157 as a valuable experimental tool for exploring coordinated tissue repair, endothelial stabilization, barrier integrity preservation, and anti-inflammatory dynamics in controlled non-human settings without invoking broader systemic hormonal influences.